We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neoadjuvant Treatment with Weekly High-Dose 5-Fluorouracil as 24-Hour Infusion, Folinic Acid and Oxaliplatin in Patients with Primary Resectable Liver Metastases of Colorectal Cancer.
- Authors
Wein; Riedel; Brückl; Merkel; Ott; Hanke; Baum; Fuchs; Günther; Reck; Papadopoulos; Hahn; Hohenberger
- Abstract
Purpose: To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC). Patients and Methods: 20 patients with primarily resectable liver metastases of CRC were enrolled in a prospective phase II study. On an outpatient basis, the patients received a treatment regimen comprising biweekly 85 mg/m[sup 2] L-OHP in the form of a 2-hour intravenous infusion and 500 mg/m[sup 2] FA as a 1- to 2-hour intravenous infusion, followed by 2,600 mg/m[sup 2 ] 5-FU administered as a 24-hour intravenous infusion once weekly. A single treatment cycle comprised one infusion per week during a period of 6 weeks followed by a 2-week rest. Two cycles were administered, with a third being added when the treatment was well tolerated. Thereafter, curative resection of the liver metastases was attempted, and the patients were followed up. Results: After neoadjuvant therapy, 2 of the original 20 patients showed complete remission (CR; 10%) and 18 patients partial remission (PR; 90%). As the main symptom of toxicity, diarrhea (CTC toxicity grade 3–4) was observed in 6 patients (30%), followed by vomiting in 3 patients (15%). The curative resectability rate was 80% (16 of 20). In 9 of 18 patients (50%) undergoing surgical intervention, mild postoperative complications, mainly wound healing disturbances (n = 5), occurred. No postoperative mortality was observed. Over a median follow-up of 23 months (12–38) 6 of 16 curatively resected patients developed distant metastases and 1 patient a local pelvic recurrence. The 2-year disease-free survival rate was 52% and the 2-year cancer-related survival rate 80%. Conclusion: The neoadjuvant treatment with weekly high-dose 5-FU in the form of a 24-hour infusion combined with FA and L-OHP is very effective and well tolerated. Surgical morbidity does not appear to be increased by the neoadjuvant treatment.Copyright © 2003 S. Karger AG, Basel
- Subjects
FLUOROURACIL; COLON cancer; LIVER metastasis; ANTINEOPLASTIC agents; METASTASIS
- Publication
Oncology, 2003, Vol 64, Issue 2, p131
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000067772